Global Pet Cancer Therapeutics 麻豆原创 Research Report 2023

Publication ID:

PB510232045

Publication Date:

October 30, 2023

Pages:

103

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Pet cancer therapeutics are the novel drug molecules that exhibit high potential to reduce the effects of cancer, giving access to comprehensive cancer care with minimum side effects. Cancer therapies aims to permanently eradicate the cancerous cells prevalent in pets. The veterinarian recommends specific treatment program such as targeted therapy and combination therapy or chemotherapy depending on the type of cancer, stage, and nature of the cancer.
The global Pet Cancer Therapeutics market is projected to reach US$ 675.4 million in 2029, increasing from US$ 396.2 million in 2022, with the CAGR of 7.9% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pet Cancer Therapeutics market research.
Pet medical care is the second largest segment in pet industry. In the UK, annual spending on veterinary and other pet services has risen from 拢2.6bn in 2015 to 拢4bn in 2021, a 54% increase in just six years. According to Vetnosis, the value of the global animal health industry will increase by 12% to $38.3 billion in 2021. White Paper on China's Pet Healthy Consumption of JD shows that in 2023, there are 13.09 million pets entering middle age and old age. And pet aging is expected to be seen in the next few years. Changes in the age structure of pets will further bring about the development of the pet medical industry. According to the data of the 2022 China Pet Medical Industry White Paper, from the perspective of market size, the scale of China's pet medical market is about 楼67.5 billion, accounting for about 22.5% of the entire pet industry. From the perspective of hospital operation time, pet hospitals within 5 years accounted for about 73%. About 11% of the pet hospitals have been in operation for more than 10 years. From the perspective of hospital turnover, nearly 40% of the hospitals have increased their annual turnover year-on-year, and the growth rate is mainly within 40%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Pet Cancer Therapeutics market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Aratana Therapeutics, Inc
AB Science
Boehringer Ingelheim International GmbH
Zenoaq
Morphogenesis, Inc
VetDC, Inc
Karyopharm Therapeutics, Inc
Rhizen Pharmaceutical SA
Regeneus Ltd.
Oasmia Pharmaceuticals AB
Zoetis
VetiVax
Ngelheim International GmbH
Elanco
Merial Inc
ELIAS Animal Health
Segment by Type
Chemotherapy
Targeted Therapy
Combination Therapy
Immunotherapy
Segment by Application
Lymphoma
Mast Cell Cancer
Melanoma
Mammary
Squamous Cell Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Pet Cancer Therapeutics report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Pet Cancer Therapeutics 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Chemotherapy
1.2.3 Targeted Therapy
1.2.4 Combination Therapy
1.2.5 Immunotherapy
1.3 麻豆原创 by Application
1.3.1 Global Pet Cancer Therapeutics 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Lymphoma
1.3.3 Mast Cell Cancer
1.3.4 Melanoma
1.3.5 Mammary
1.3.6 Squamous Cell Cancer
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pet Cancer Therapeutics 麻豆原创 Perspective (2018-2029)
2.2 Pet Cancer Therapeutics Growth Trends by Region
2.2.1 Global Pet Cancer Therapeutics 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Pet Cancer Therapeutics Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Pet Cancer Therapeutics Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Pet Cancer Therapeutics 麻豆原创 Dynamics
2.3.1 Pet Cancer Therapeutics Industry Trends
2.3.2 Pet Cancer Therapeutics 麻豆原创 Drivers
2.3.3 Pet Cancer Therapeutics 麻豆原创 Challenges
2.3.4 Pet Cancer Therapeutics 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pet Cancer Therapeutics Players by Revenue
3.1.1 Global Top Pet Cancer Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Pet Cancer Therapeutics Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Pet Cancer Therapeutics 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pet Cancer Therapeutics Revenue
3.4 Global Pet Cancer Therapeutics 麻豆原创 Concentration Ratio
3.4.1 Global Pet Cancer Therapeutics 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pet Cancer Therapeutics Revenue in 2022
3.5 Pet Cancer Therapeutics Key Players Head office and Area Served
3.6 Key Players Pet Cancer Therapeutics Product Solution and Service
3.7 Date of Enter into Pet Cancer Therapeutics 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Pet Cancer Therapeutics Breakdown Data by Type
4.1 Global Pet Cancer Therapeutics Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Pet Cancer Therapeutics Forecasted 麻豆原创 Size by Type (2024-2029)
5 Pet Cancer Therapeutics Breakdown Data by Application
5.1 Global Pet Cancer Therapeutics Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Pet Cancer Therapeutics Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Pet Cancer Therapeutics 麻豆原创 Size (2018-2029)
6.2 North America Pet Cancer Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Pet Cancer Therapeutics 麻豆原创 Size by Country (2018-2023)
6.4 North America Pet Cancer Therapeutics 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pet Cancer Therapeutics 麻豆原创 Size (2018-2029)
7.2 Europe Pet Cancer Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Pet Cancer Therapeutics 麻豆原创 Size by Country (2018-2023)
7.4 Europe Pet Cancer Therapeutics 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pet Cancer Therapeutics 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Pet Cancer Therapeutics 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Pet Cancer Therapeutics 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Pet Cancer Therapeutics 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pet Cancer Therapeutics 麻豆原创 Size (2018-2029)
9.2 Latin America Pet Cancer Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Pet Cancer Therapeutics 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Pet Cancer Therapeutics 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pet Cancer Therapeutics 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Pet Cancer Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Pet Cancer Therapeutics 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Pet Cancer Therapeutics 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Aratana Therapeutics, Inc
11.1.1 Aratana Therapeutics, Inc Company Detail
11.1.2 Aratana Therapeutics, Inc Business Overview
11.1.3 Aratana Therapeutics, Inc Pet Cancer Therapeutics Introduction
11.1.4 Aratana Therapeutics, Inc Revenue in Pet Cancer Therapeutics Business (2018-2023)
11.1.5 Aratana Therapeutics, Inc Recent Development
11.2 AB Science
11.2.1 AB Science Company Detail
11.2.2 AB Science Business Overview
11.2.3 AB Science Pet Cancer Therapeutics Introduction
11.2.4 AB Science Revenue in Pet Cancer Therapeutics Business (2018-2023)
11.2.5 AB Science Recent Development
11.3 Boehringer Ingelheim International GmbH
11.3.1 Boehringer Ingelheim International GmbH Company Detail
11.3.2 Boehringer Ingelheim International GmbH Business Overview
11.3.3 Boehringer Ingelheim International GmbH Pet Cancer Therapeutics Introduction
11.3.4 Boehringer Ingelheim International GmbH Revenue in Pet Cancer Therapeutics Business (2018-2023)
11.3.5 Boehringer Ingelheim International GmbH Recent Development
11.4 Zenoaq
11.4.1 Zenoaq Company Detail
11.4.2 Zenoaq Business Overview
11.4.3 Zenoaq Pet Cancer Therapeutics Introduction
11.4.4 Zenoaq Revenue in Pet Cancer Therapeutics Business (2018-2023)
11.4.5 Zenoaq Recent Development
11.5 Morphogenesis, Inc
11.5.1 Morphogenesis, Inc Company Detail
11.5.2 Morphogenesis, Inc Business Overview
11.5.3 Morphogenesis, Inc Pet Cancer Therapeutics Introduction
11.5.4 Morphogenesis, Inc Revenue in Pet Cancer Therapeutics Business (2018-2023)
11.5.5 Morphogenesis, Inc Recent Development
11.6 VetDC, Inc
11.6.1 VetDC, Inc Company Detail
11.6.2 VetDC, Inc Business Overview
11.6.3 VetDC, Inc Pet Cancer Therapeutics Introduction
11.6.4 VetDC, Inc Revenue in Pet Cancer Therapeutics Business (2018-2023)
11.6.5 VetDC, Inc Recent Development
11.7 Karyopharm Therapeutics, Inc
11.7.1 Karyopharm Therapeutics, Inc Company Detail
11.7.2 Karyopharm Therapeutics, Inc Business Overview
11.7.3 Karyopharm Therapeutics, Inc Pet Cancer Therapeutics Introduction
11.7.4 Karyopharm Therapeutics, Inc Revenue in Pet Cancer Therapeutics Business (2018-2023)
11.7.5 Karyopharm Therapeutics, Inc Recent Development
11.8 Rhizen Pharmaceutical SA
11.8.1 Rhizen Pharmaceutical SA Company Detail
11.8.2 Rhizen Pharmaceutical SA Business Overview
11.8.3 Rhizen Pharmaceutical SA Pet Cancer Therapeutics Introduction
11.8.4 Rhizen Pharmaceutical SA Revenue in Pet Cancer Therapeutics Business (2018-2023)
11.8.5 Rhizen Pharmaceutical SA Recent Development
11.9 Regeneus Ltd.
11.9.1 Regeneus Ltd. Company Detail
11.9.2 Regeneus Ltd. Business Overview
11.9.3 Regeneus Ltd. Pet Cancer Therapeutics Introduction
11.9.4 Regeneus Ltd. Revenue in Pet Cancer Therapeutics Business (2018-2023)
11.9.5 Regeneus Ltd. Recent Development
11.10 Oasmia Pharmaceuticals AB
11.10.1 Oasmia Pharmaceuticals AB Company Detail
11.10.2 Oasmia Pharmaceuticals AB Business Overview
11.10.3 Oasmia Pharmaceuticals AB Pet Cancer Therapeutics Introduction
11.10.4 Oasmia Pharmaceuticals AB Revenue in Pet Cancer Therapeutics Business (2018-2023)
11.10.5 Oasmia Pharmaceuticals AB Recent Development
11.11 Zoetis
11.11.1 Zoetis Company Detail
11.11.2 Zoetis Business Overview
11.11.3 Zoetis Pet Cancer Therapeutics Introduction
11.11.4 Zoetis Revenue in Pet Cancer Therapeutics Business (2018-2023)
11.11.5 Zoetis Recent Development
11.12 VetiVax
11.12.1 VetiVax Company Detail
11.12.2 VetiVax Business Overview
11.12.3 VetiVax Pet Cancer Therapeutics Introduction
11.12.4 VetiVax Revenue in Pet Cancer Therapeutics Business (2018-2023)
11.12.5 VetiVax Recent Development
11.13 Ngelheim International GmbH
11.13.1 Ngelheim International GmbH Company Detail
11.13.2 Ngelheim International GmbH Business Overview
11.13.3 Ngelheim International GmbH Pet Cancer Therapeutics Introduction
11.13.4 Ngelheim International GmbH Revenue in Pet Cancer Therapeutics Business (2018-2023)
11.13.5 Ngelheim International GmbH Recent Development
11.14 Elanco
11.14.1 Elanco Company Detail
11.14.2 Elanco Business Overview
11.14.3 Elanco Pet Cancer Therapeutics Introduction
11.14.4 Elanco Revenue in Pet Cancer Therapeutics Business (2018-2023)
11.14.5 Elanco Recent Development
11.15 Merial Inc
11.15.1 Merial Inc Company Detail
11.15.2 Merial Inc Business Overview
11.15.3 Merial Inc Pet Cancer Therapeutics Introduction
11.15.4 Merial Inc Revenue in Pet Cancer Therapeutics Business (2018-2023)
11.15.5 Merial Inc Recent Development
11.16 ELIAS Animal Health
11.16.1 ELIAS Animal Health Company Detail
11.16.2 ELIAS Animal Health Business Overview
11.16.3 ELIAS Animal Health Pet Cancer Therapeutics Introduction
11.16.4 ELIAS Animal Health Revenue in Pet Cancer Therapeutics Business (2018-2023)
11.16.5 ELIAS Animal Health Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Aratana Therapeutics, Inc
AB Science
Boehringer Ingelheim International GmbH
Zenoaq
Morphogenesis, Inc
VetDC, Inc
Karyopharm Therapeutics, Inc
Rhizen Pharmaceutical SA
Regeneus Ltd.
Oasmia Pharmaceuticals AB
Zoetis
VetiVax
Ngelheim International GmbH
Elanco
Merial Inc
ELIAS Animal Health

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.